JMP Securities analyst Silvan Tuerkcan maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) today and set a price target of $70.00. The company’s shares closed today at $50.75.
According to TipRanks, Tuerkcan is a 3-star analyst with an average return of 3.0% and a 36.67% success rate. Tuerkcan covers the Healthcare sector, focusing on stocks such as Mirati Therapeutics, Crispr Therapeutics AG, and Vor Biopharma.
Currently, the analyst consensus on Crispr Therapeutics AG is a Moderate Buy with an average price target of $91.30.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $86.95 and a one-year low of $38.94. Currently, Crispr Therapeutics AG has an average volume of 1.08M.
Based on the recent corporate insider activity of 16 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CRSP in relation to earlier this year. Last month, Kulkarni Samarth, the CEO of CRSP bought 58,233.00 shares for a total of $105,401.73.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.
Read More on CRSP:
- Crispr Therapeutics price target lowered to $70 from $100 at JMP Securities
- CRISPR Therapeutics to Participate in B. Riley Securities’ 3rd Annual Oncology Conference
- Crispr Therapeutics call volume above normal and directionally bullish
- Crispr Therapeutics initiated with a Buy at EF Hutton
- Crispr Therapeutics appoints Harding as SVP, Head of Business Development
